


INTERNATIONAL SUMMIT ON NEURODEGENERATIVE DISEASES



"Dancing astrocytes"

Champalimaud Foundation
Lisbon, September 19-21

PRELIMINARY SCIENTIFIC PROGRAM

Thursday, September 19

Early detection of the pathological components leading to cognitive deterioration

8:30 – 9:00 **Registration**

9:00 - 11:30 **Scientific Session I: Neuropathology**

We will start with a neuropathology session proposing that co-pathology is the norm in dementia, and most patients have several components: tau, amyloid, TDP-43, alpha-synuclein.

CHAIRPERSON: Alberto Rábano. BTCIEN-Fundación CIEN.

Sandra Oliveira Tomé. KU-Leuven
"Title"

Gabor Kovacs. Laboratory Medicine & Pathobiology. University of Toronto. (On-line)
"Title"

Diego Sepúlveda. UKE Hamburg
"Title"

Ed Lein. Allen Institute, Seattle
"Single cell transcriptomics & disease progression in Alzheimer's Disease"

11:30 - 12:00 **Break & posters**

12:00 – 13:00 **Scientific Session II: Genetic variability**

In the following session, we will address how genetic variability is associated with the risk of AD and some of the most frequent co-pathologies (alpha-synuclein, TDP43, vascular...) and how it can potentially be used for diagnostic and/or risk classification. We will also explore brain resilience from a genetic perspective.

CHAIRPERSON: Agustín Ruiz Fundació ACE-CIBERNED

Alfredo Ramírez. Cluster of Excellence for Aging Research. University of Cologne.
"Title"

Henne Holstege. Alzheimer Center Amsterdam. VUmc. Amsterdam UMC.
"Title"

13:00 - 15:00 **Lunch & posters**

15:00 – 16:30 **SCIENTIFIC SESSION III: Neuroimaging**

We will deepen into neuroimaging techniques for detecting different dementia-related brain alterations reflecting distinct pathologic components.

CHAIRPERSON: Michel Grothe. Fundación CIEN

David Wolk. Laboratory for Cognition and Neural Stimulation. University of Pennsylvania.
"Title"

Jesús Silva. Fundación CIEN.
"Title"

Laura Jonkman. Amsterdam Neuroscience - Brain Imaging (VUmc). Amsterdam UMC
"Title"

16:30 - 17:00 **Coffee break & posters**

17:00 – 18:30 **SCIENTIFIC SESSION IV: Biomarkers**



PRELIMINARY SCIENTIFIC PROGRAM

Discussing the detection of neuropathological components in the periphery using biochemical markers.

CHAIRPERSON: Pascual Sánchez Juan. Fundación CIEN.

Gemma Salvadó. Clinical Memory Research. Lund University.

"Title"

Anja Schneider. Translational Dementia Research. German Center for Neurodegenerative Diseases-DZNE. University of Bonn.

"Title"

Marc Suarez. Barcelona Beta Brain Research

"Title"

PRELIMINARY SCIENTIFIC PROGRAM

Friday, September 20

Personalized Interventions. Secondary prevention

9:30-11:00

Scientific Session V: Pharmacological intervention

We will discuss pharmacological interventions, specifically tackling some of the main pathological components of dementia.

CHAIRPERSON: Alberto Lleó. Unidad de Memoria. Hospital de Sant Pau - Luisa Alves – Universidade NOVA de Lisboa

Malú Gamez Tansey. Center for Translational research in Neurodegenerative disease. University of Florida.

“Targeting immune dysfunction and chronic inflammation”

Tiago Outeiro. Goettingen University Germany

“Title”

Catherine Mummery. University College London

“Title”

11:00- 11: 30

Coffee break & posters11:30 – 13:00 Scientific Session VI: Non-pharmacological interventions

Non-pharmacological interventions. Here, we will discuss non-pharmacological interventions and the available evidence of how these address specific pathological components.

CHAIRPERSON: Joaquim Ferreira. CNS – Campus Neurológico. University of Lisbon.

Pablo Martínez Lage. Fundación CITA Alzheimer. Donostia.

“Title”

Giacomo Koch. Foundation Santa Lucia., Rome, Italy

“Title”

Arianne Gravestein. Amsterdam UMC, The Netherlands.

“Title”

13:00 - 15:00

Lunch & posters

15:00 - 16:30

Scientific Session VII: Digital Therapies in assessment and interventions

CHAIRPERSON: John Krakauer. Champalimaud Foundation & Johns Hopkins University.

Daniela Pimenta da Silva. CNS, Portugal

“Inferring health and disease outcomes based on the real-world behaviour captured on smartphones”

Arko Ghosh. Leiden University, The Netherlands

“Title”

Dina Katabi. Massachusetts Institute of Technology, USA.

“Title”

16:30 - 17:00

Coffee break & posters

PRELIMINARY SCIENTIFIC PROGRAM

17:00-18:00

Posters

PRELIMINARY SCIENTIFIC PROGRAM

Saturday, September 21

Patient's perspective

9:30-11:30 Session I: People living with AD and PD – The patient at the center of care and their engagement in research

In this session we will have two short presentations by representatives from an Alzheimer's Disease patient association and a Parkinson's Disease patient association followed by a round table with patients, patient associations, clinicians and researchers from Spain and Portugal.

MODERATOR: Marcelo Mendonça. Champalimaud Foundation.

Patient associations: **Josefa Domingos** (Parkinson's Europe and Young Parkies Portugal), **Maria do Rosário Zincke** (Alzheimer Europe and Associação Alzheimer Portugal), **Mariló Almagro**, Confederación Española de Alzheimer y otras demencias (CEAFA), **Kina García**, Panel de expertos de personas con Alzheimer (PEPA), **Alicia Campos**, Federación Española Parkinson.

Neurologists / Researchers: **Isabel Santana**, Faculdade de Medicina, Universidade de Coimbra; **Alberto Lleó**, Unidad de Memoria. Hospital de Sant Pau; **Pascual Sánchez-Juan**, Fundación CIEN; **Joaquim Ferreira**, CNS – Campus Neurológico. University of Lisbon.

Geneticists: **Agustín Ruiz**, Fundació ACE.

11:30- 12:00 Coffee break & posters

12:00 – 13:30 OFFICIAL CLOSING BY HER MAJESTY QUEEN SOFÍA OF SPAIN

13:15 End of meeting

PRELIMINARY SCIENTIFIC PROGRAM

Fundación CIEN SECRETARIAT:



Almudena Flores Junquera
Beatriz Salado Martínez
Aina Frontera Sánchez
c/ Valderrebollo, 5 – 28031 Madrid
congreso@fundacioncien.es
Phone: (+34) 91 385 22 00

CONGRESS SECRETARIAT:

VENUE:

Champalimaud Foundation
Av. Brasília, 1400-038 Lisboa, Portugal



GOLD SPONSOR:

